Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Dividends declared (per SOCE filings): FY2022 46,044 · FY2023 0 · FY2024 0 — 3-yr total 46,044
GM Pharmaceuticals LLC (GMP) is Georgia's largest pharmaceutical manufacturer, producing ~140 brands across 230+ dosage forms at its Ponichala (Tbilisi) plant — the largest pharma facility in the South Caucasus. Exports across the CIS with 600+ employees.
| Line item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Net Cash from Operating Activities | 12,439 | 16,617 | 11,827 | 22,822 | 38,863 | 16,157 | 1,009 | 10,288 | -2.7% |
| Net Cash used in Investing Activities | 0 | 8,442 | 10,681 | 3,932 | 3,810 | 5,659 | 5,847 | 5,169 | -7.9% |
| Free Cash Flow (OCF − Capex proxy) | 12,439 | 8,175 | 1,146 | 18,890 | 35,053 | 10,498 | 6,856 | 5,119 | -11.9% |
| Net Cash from Financing Activities | 0 | 4,444 | 626 | 458 | 391 | 507 | 437 | 667 | -27.1% |
| Net Change in Cash (before FX) | 12,439 | 3,731 | 519 | 18,432 | 34,662 | 9,991 | 7,293 | 4,452 | -13.7% |
| Effect of FX on Cash | 0 | 142 | 113 | 548 | 2,899 | 12,127 | 3,922 | 752 | nmf |
| Net Change in Cash (incl. FX) | 12,439 | 3,589 | 632 | 18,980 | 31,763 | 2,136 | 11,214 | 5,204 | -11.7% |
| Cash at Beginning of Year | 0 | 531 | 4,120 | 4,752 | 23,732 | 55,495 | 53,359 | 42,144 | +107.3% |
| Cash at End of Year | 0 | 4,120 | 4,752 | 23,732 | 55,495 | 53,359 | 42,144 | 47,348 | +50.2% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →